In the growing rare disease precision medicine market, drug companies must avoid funding genetic testing that the Justice ...

The partners have committed to awarding two grants, totaling around $2.3 million, to researchers studying this lung cancer subset.

The project will leverage Noetik's AI model and multimodal spatial data to search for biomarkers of patient response to Agenus' immunotherapy regimen.

Verve is developing drug candidates for heart disease, including the PCSK9-targeted VERVE-102, a base-editing therapy.